IOV - Istituto Oncologico Veneto IRCCS - Oncologia Medica 2

Padova

0 studies enrolling now · 3 studies all time

What they study most

Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Neoplasms

Studies at this site

• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) — Running, not enrolling
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) — Stopped early
• Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer — Stopped early